Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...
There is a new chapter in Big Pharma’s billion-dollar war on obesity, as NovoNordisk and Eli Lilly battle it out over the latest blockbuster drugs. Ozempic maker NovoNordisk’s highly ...
Some results have been hidden because they may be inaccessible to you